New Clinical Study of Phenoxodiol as Chemo-sensitizer for Docetaxel in Ovarian Cancer Commences at Yale Univ School of Medicine
28th Nov 2005, 23:00 GMT
Combination Therapy Study to Address Major Need in Jumping Hurdle of Resistance to Standard Treatments
New Clinical Study of Phenoxodiol as Chemo-sensitizer for Docetaxel in Ovarian Cancer Commences at Yale Univ School of Medicine related news:
- New Clinical Study of Phenoxodiol as Chemo-sensitizer for Docetaxel in Ovarian Cancer Commences at Yale University School of Medicine — PR Newswire: All Releases
- Major ovarian cancer clinical study announced at Yale using combination drug therapy, phenoxodiol with docetaxel — Medical News Today RSS/XML Feed
- Major Ovarian Cancer Clinical Study Announced At Yale Using Combination Drug Therapy — ScienceDaily Headlines
- Marshall Edwards initiates trial of chemo-sensitizer — Pharmaceutical Business Review Online
- Ginkgo biloba does more than help with memory — The Cancer Blog
- Researchers Discover Molecular Differences Between Low-grade and High-grade Ovarian Cancers — Kansas City infoZine Health Headlines
- Restructuring of Milwaukee Clinical Campus continues — Physician News News from StratCenter.com
- Study compares Canadian and US heart failure survival rates — The Earth Times Online Newspaper - Health News
- Study looks at factors influencing African-American women's decisions to join cancer screening trial — KeralaNext: Science
- Factors Influencing African-American Women's Decisions To Join Cancer Screening Trial, Study — Medical News Today RSS/XML Feed
Latest news from Operations-Related News from StratCenter.com:
- Senior Housing Properties Trust Announces Proposed Public Offering of 5 mln Common Shares
- King Not Loving Its Shareholders
- Sepracor says asthma drug data is favorable
- Sepracor Presents Data on Asthma Drug
- Dr Reddy's Registers to List Shares
- PolyMedica Corp CEO to Ring the NASDAQ Stock Market Opening Bell
- Biovail to Present at the CSFB 2006 Healthcare Conference
- Genelabs reports lower Q3 loss
- Solexa posts narrowed Q3 loss
- Abbott's Humira Positive in 2 Studies